NewAmsterdam Pharma Stock Soars 5.25% on Bullish Analyst Ratings

On June 18, 2025, NewAmsterdam Pharma's stock surged by 5.25% in pre-market trading, reflecting a strong bullish sentiment among investors.

Citigroup has initiated coverage on NewAmsterdam Pharma, assigning it a 'Buy' rating and setting a target price of $42. The firm highlights the significant unmet need in the LDL cholesterol lowering market, where a substantial portion of patients with atherosclerotic cardiovascular disease still require additional therapies to reach their targeted LDL-C levels. NewAmsterdam's obicetrapib is positioned as a first-in-class agent that could be used as an add-on to statins or in combination therapy with ezetimibe for those needing further lipid lowering.

Needham & Company LLC has also reissued a 'buy' rating on NewAmsterdam Pharma, setting a price target of $40. This reiteration of a positive outlook underscores the growing confidence in the company's potential within the biotech sector.